The George Washington University Medical Center

Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA GREENWICH, Conn.--(BUSINESS WIRE)-- Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer. Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA. During his more than 20-year career at the FDA, he was responsible for the review of dozens of NDAs and hundreds of INDs for drugs and drug-device combination products for treatment or prevention of cardiovascular diseases. He was also responsible for organizing meetings of the Cardiovascular and Renal Drugs Advisory Committee and participated in working groups that wrote guidance and regulations for drug development. This press release features multimedia. View the full release here: Stephen Grant, MD (Photo: Business Wire) "We are honored and privileged to work with Dr. Grant. His guidance and his wealth of regulatory experience in the cardio-renal area at the FDA will tremendously benefit our mission to bring ST-62516 to patients,” said Anna Kazanchyan, MD, Founder and CEO of Saghmos. “Impaired kidney function is associated with a high risk of morbidity and mortality after percutaneous coronary intervention (PCI). Hence providers must frequently make a difficult choice in this population between not performing PCI, even when indicated, or exposing patients to the risk of complications,” Stephen Grant, MD, said. “In this context, a drug such as trimetazidine will be a useful addition to the treatment armamentarium to prevent complications after PCI. I am excited about working with Saghmos to bring this drug to patients.” Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as PCI. Saghmos’ IND for ST-62516 was cleared by the FDA in 2023. Over one million PCI procedures are performed annually in the US in patients with unstable angina (heart attack). About half of these patients have comorbidities which impact the safety of PCI. This is a major unmet medical need with no FDA-approved drugs available to prevent or treat AKI and MACKE. ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI. About Stephen Grant, MD Stephen Grant, MD, is the former Deputy Director, Division of Cardiology and Nephrology at the Center for Drug Evaluation and Research (CDER) of the FDA. During his more than 20-year career at FDA, he was also Clinical Team Leader and Clinical Reviewer at the Division of Cardiology and Nephrology. In addition, he served in leadership roles at the Center for Biologics Evaluation and Research (CBER). Prior to his career at the FDA, Dr. Grant was a practicing cardiologist. Dr. Grant received his MD from Harvard Medical School and completed his residency in Internal Medicine at The George Washington University Medical Center. He is Board-certified in Internal Medicine, Cardiovascular Subspecialty, and completed a cardiology fellowship at The George Washington University Medical Center. In addition, he did a medical fellowship at the National Heart, Lung and Blood Institute, National Institutes of Health, where he was a member of the team that cloned and sequenced apolipoprotein B-100 (apoB), a protein that carries fat and cholesterol around the body. About Saghmos Therapeutics Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. The company has an issued US patent (Patent number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures and has received Notice of Allowance for a second US patent. Forward looking statements This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics’ business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward-looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

BETHESDA, Md., Oct. 24, 2022 /PRNewswire/ -- Michael K. Rosner, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional in the Medical field for his outstanding career in Neurosurgery and in acknowledgment of his work at George Washington University Hospital. Continue Reading Michael K. Rosner, MD A board-certified neurosurgeon, Dr. Rosner has been practicing since 2003. He has been with George Washington University Hospital in Washington, D.C., for seven years and is affiliated with George Washington University Medical Faculty Associates. As a professor of neurological surgery, he is currently the interim chair of the GW Department of Neurological Surgery. Dr. Rosner leads the neurological surgery department's activities as the GW academic health care enterprise continues its journey to pre-eminence as a health care provider in the nation's capital. As part of the leadership team of the GW MFA and SMHS, he is responsible for growing the clinical and academic footprint of the department and bolstering the department's local, national, and global reputation. Dr. Rosner has several clinical and research interests in spinal column disorders and neuro-trauma. His clinical interests include complex spine disorders such as scoliosis and kyphoscoliosis of all age groups, degenerative spinal pathology, revision spine surgery, deformity correction, spinal oncology, minimally invasive spine surgery, and neuro-trauma. His current management style utilizes a multidisciplinary approach to managing spinal column disorders. Before embarking on his professional journey, Dr. Rosner received a Bachelor of Science degree in Biomedical Engineering from Marquette University in Milwaukee, WI. A graduate of the Medical College of Wisconsin in 1995, he completed a surgical internship at Walter Reed Army Medical Center in Washington, D.C. the following year. After a research fellowship at the Walter Reed Army Institute of Research in 1999 and residency training in neurological surgery at Walter Reed Army Medical Center in 2002, he completed a fellowship in complex and reconstructive spine surgery at Northwestern University in Evanston, IL in 2003. After fellowship training, Dr. Rosner was a staff neurosurgeon at Walter Reed and deployed in 2003 to Landstuhl Regional Medical Center in Germany. He was subsequently deployed in 2005 to the 86th Combat Support Hospital in Baghdad, Iraq, in support of Operation Iraqi Freedom. In 2006, he was selected as Chief of Neurosurgery at Walter Reed. Later, he was chosen as the Integrated Chief of Neurosurgery at Walter Reed National Military Medical Center. Retiring from the U.S. Army in 2015, Dr. Rosner was honored to serve our country during his active-duty years. Dr. Rosner attributes his success to his military background. As a professor of neurosurgery and interim department chair, the doctor enjoys teaching and mentoring medical students and residents. He will likely become the official chair of the neurosurgery department this year. He hopes to build up the department, as he did at Walter Reed. Among his awards and honors, Dr. Rosner was the Spinal Deformity Education Group (SDEG) Traveling Fellow in 2004 and received the General Hayes Award for the outstanding attending surgeon who exemplifies devotion to the NNC Neurosurgical Residency Program in 2004, 2006, 2007, and 2013. He was awarded the General Chennault Award in 2009 as the most outstanding teaching faculty at Walter Reed Army Medical Center. Board-certified through the American Board of Neurological Surgery, Dr. Rosner is a Fellow of the American Association of Neurological Surgeons. He is also a member of the Congress of Neurological Surgeons, the Society of Neurological Surgeons, the Scoliosis Research Society, and the North American Spine Society. The recipient of several research grants, Dr. Rosner is the principal investigator of numerous laboratory and clinical research studies. He has published many peer-reviewed journal articles and book chapters and has been actively involved with organized neurosurgery on the national level. He served on the Executive Committee of the AANS/CNS Spine Section and was previously chair of the SRS research committee. On a personal note, Dr. Rosner is married to Dr. Inger (Lerra) Rosner, a board-certified urologic oncologist working at the Inova Schar Cancer Institute. They have three sons and live in Bethesda, MD. Outside of work, Dr. Rosner enjoys spending quality time with his family. For more information, visit . For more information, visit . Contact: Katherine Green, 516-825-5634, [email protected] SOURCE Continental Who's Who

Tampa, Florida, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Oncology informatics company, Inspirata, is pleased to announce the recent addition of a new key member to the company’s leadership team. Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. This includes combining insights from her own industry experiences with feedback from the market to inform product strategy and refine market positioning. “I look forward to collaborating with Sales, Marketing, Product Design and Software Development to ensure future product enhancements are well aligned with market requirements and solve our customers’ most pressing issues related to matching oncology patients to clinical trials,” said Laurie Smith in relation to her new role. On top of her strong enthusiasm for applications of AI and NLP technology in clinical decision support, Laurie brings a wealth of first-hand clinical research and patient pre-screening experience. Most recently, Laurie was a Vice President for Clinical Research Services at Roswell Park Comprehensive Cancer Center. Prior to that, she had served for three decades at prominent healthcare institutions, such as AMITA Health, Rush University Medical Center, University of Chicago, Siteman Cancer Center Clinical Trials Office, and Washington University Medical Center. “We are delighted to have someone of Laurie Smith’s caliber and experience step into this critical role,” said Satish Sanan, CEO of Inspirata. “We are confident we have found the right leader to centralize our subject matter expertise in the clinical research area, serve as an influential product evangelist, and oversee our new Advisory Board for Inspirata’s clinical trial matching solutions.” Laurie has a Master’s degree in Management and Leadership from Webster University where she also served as an Adjunct Faculty Instructor between 1993 and 2002. At various points in time, she was a member of the Schulman Associates Institutional Review Board, Rush University Cancer Research Committee, University of Chicago Cancer Center Scientific Review Committee, Washington University Protocol Review and Monitoring Committee, CALGB CRA Core Committee, and CALGB Audit Committee. About Inspirata Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship. Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated clinical trial matching and cancer registry solutions to bring users the broadest oncology informatics platform available globally. To learn more, visit . Inspirata Contact: Emil Mladenov Vice President of Corporate and Digital Marketing Email: emladenov@inspirata.com Tel: +1-813-570-8914 Emil Mladenov Inspirata, Inc. +1-813-570-8914 emladenov@inspirata.com